The improved cardiovascular safety of omnic (tamsulosin) oral controlled absorption system (OCAS®)

被引：3

作者：

Korstanje, C ^{[1
]}

机构：

[1] Astellas Europe BV, Dept Dev Biol, NL-2350 AC Leiden, Netherlands

来源：

EUROPEAN UROLOGY SUPPLEMENTS | 2005年 / 4卷 / 07期

关键词：

tamsulosin; controlled release formulation; oral controlled absorption system; modified release formulation; receptors adrenergic alpha 1; vasoconstriction; orthostatic hypotension;

D O I：

10.1016/j.eursup.2005.07.003

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：10 / 13

页数：4

共 11 条

[1] Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system [J].

Barendrecht, MM ;

Koopmans, RP ;

De La Rosette, JJMCH ;

Michel, MC .

BJU INTERNATIONAL, 2005, 95 :19-28

[2] The development of the oral controlled absorption system (OCAS®):: A new improved formulation of tamsulosin [J].

Chapple, CR .

EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (07) :1-4

[3] Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH):: Efficacy and tolerability in a placebo and active comparator controlled phase 3a study [J].

Chapple, CR ;

Al-Shukri, SH ;

Gattegno, B ;

Holmes, S ;

Martínez-Sagarra, JM ;

Scarpa, RM ;

Trip, OBV ;

Vik, V ;

van der Putten-Slob, I .

EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (02) :33-44

[4] Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): Efficacy and tolerability in a phase 2b dose-response study [J].

Chapple, CR ;

Lorenz, J ;

Mortensen, R ;

Pauthner, H ;

Reise, MO ;

Schulman, CC ;

van der Putten-Slob, I .

EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (02) :25-32

[5]

Coffey DS, 1998, BRIT J UROL, V81, P1

[6] The pharmacokinetic profile of tamsulosin oral controlled absorption system (OCAS®) [J].

Michel, MC ;

Korstanje, C ;

Krauwinkel, W ;

Kuipers, M .

EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (02) :15-24

[7] Comparison of vascular α1-adrenoceptor antagonism of tamsulosin in oral controlled absorption system (OCAS) and modified release (MR) formulations [J].

Michel, MC ;

Korstanje, C ;

Krauwinkel, W ;

Shear, M ;

Davies, J ;

Quartel, A .

EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (02) :45-52

[8] Cardiovascular safety of the oral controlled absorption system (OCAS) formulation of tamsulosin compared to the modified release (MR) formulation [J].

Michel, MC ;

Korstanje, C ;

Klauwinkel, W ;

Shear, M ;

Davies, J ;

Quartel, A .

EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (02) :53-60

[9] Use of α-blockers and the risk of hip/femur fractures [J].

Souverein, PC ;

Van Staa, TP ;

Egberts, ACG ;

De la Rosette, JJMCH ;

Cooper, C ;

Leufkens, HGM .

JOURNAL OF INTERNAL MEDICINE, 2003, 254 (06) :548-554

[10] The clinical development of omnic (tamsulosin) oral controlled absorption system (OCAS®) [J].

Speakman, M .

EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (07) :5-9

← 1 2 →